AMPYRA for MS: Acorda Therapeutics announces wholesale pricing and patient assistance program Acorda Therapeutics, Inc. AMPYRA was on January 22 authorized, 2010 by the U.S online-apotek . Drug and Food Administration as cure to improve walking in sufferers with multiple sclerosis . This is demonstrated by a rise in walking speed. AMPYRA is likely to be available in March 2010. And of income regardless, people with personal insurance can benefit from our co-pay program, wherever allowed for legal reasons.D., President and CEO of Acorda Therapeutics. And no matter income, people with private insurance can reap the benefits of our co-pay program, wherever allowed by law.
Furthermore to launching AMICAS RIS Version 5. AMICAS Payer Solutions, which provides insurance eligibility and promises and coding compliance administration services. AMICAS Patient Solutions, which automates patient collections with printing and mail providers for communicating with patients, online statement review, come back mail automation, and an online payment portal for use by practices and individuals. AMICAS Dashboards, which is a Web-centered business intelligence platform that provides usage of customized, near real time, easy-to-read data for crucial efficiency metrics and indicators. AMICAS PACS, which drives significant improvements in radiologist productivity while allowing improvements in the quality of care.